History

June 2015

Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne

Press release

January 2015

Atlas Genetics reels in $20M in Series C round for rapid infectious disease tests

Publication

December 2014

RMI Partners has joined Series C round of financing in Transcend Medical, Inc., the company which has developed CyPass, a unique device for Minimally Invasive Glaucoma Surgery (MIGS)

September 2014

Clearside Biomedical, Inc. Completes $16 Million Series B Financing 

Press-release

July 2014

Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine

Press-release

February 2014

Miramar Labs Secures $10 Million in Series D Funding

Press-release

October 2013

NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine 

Press-release

July 2013

RusnanoMedInvest, Domain Associates and investor syndicate back ReVision Optics vision correction technology with $55 mln investment.

Press-release

Press about

December 2012

RusnanoMedInvest and Domain Associates to invest $93m in development of three next-generation pharmaceuticals.

Press-release

Press about

December 2012

Financing Deal of the Year Nominee: Rusnano/Domain and CoDa Therapeutics.

October 2012

IV Special autumn session WHAT'S GOING ON IN THE PHARMACEUTICAL MARKET: LEADERS IN SEARCH OF EFFICIENCY.

Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive network of venture investors in the sector here in Russia.

June 2012

St. Petersburg International Economic Forum - 2012

Leonid Melamed:  Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets.

June 2012

Announcement of the first RusnanoMedInvest transaction - acquisition of shares of CoDa Therapeutics, Inc. (USA. CoDa is developing Nexagon, an innovative chronic wound healing solution with targeted applications in diabetic foot ulcers, venous leg ulcers and other chronic wound pathologies.

Press-release

Press about

March 2012

RUSNANO JSC and U.S. venture fund Domain Associates announced the launch of their joint investment program, as a result of which RusnanoMedInvestwas founded. 

The agreement between RUSNANO JSC and Team Drive on the management and operation of the RusnanoMedInvest investment program was signed.

More information about RusnanoMedInvest

Press-release

Press about

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.  

All news